))
Part Two: How Innovation Can Broaden Access and Propel the CGT Industry Forward
Manage episode 441419039 series 2994360
Innhold levert av Adam.Roberts@ttp.com and TTP plc. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Adam.Roberts@ttp.com and TTP plc eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
In Part One of this two-part series, we reflected on the progress made in the Cell and Gene Therapy (CGT) industry and the importance of patient-centric development. In this episode, we dive into how we can continue to move forward, broaden access, and encourage the development of new treatments. We’ll discuss the critical need to scale manufacturing, even in the early stages of development, to ensure that these therapies reach the patients who need them.
Guests:
- Emma Chan, Director of Technical Development at Orchard Therapeutics
- Matt Hewitt, Chief Technical Officer at the Manufacturing Business Division at Charles River Laboratories
23 episoder
Del
